SIRPA and acute myeloid leukemia: While CD47/SIRPα immune checkpoint-based immunotherapy studies have shown promising preliminary results in R/R AML, the development of CD47 monoclonal antibodies still faces safety concerns and a lack of published data on therapeutic effectiveness.